Recombinant ICOSLG 抗体
Our Local Distributor
北京 101111
Quick Overview for Recombinant ICOSLG 抗体 (ABIN7881170)
抗原
See all ICOSLG 抗体抗体类型
适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
原理
- ICOSLG Antibody / CD275
-
纯化方法
- Affinity-chromatography
-
免疫原
- A synthesized peptide derived from human CD275 was used as the immunogen for the ICOSLG antibody.
-
亚型
- IgG
-
-
anti-Inducible T-Cell Co-Stimulator Ligand (ICOSLG) (AA 23-249) antibody
ICOSLG 适用: 人 WB, IHC 宿主: 兔 Polyclonal unconjugated
anti-Inducible T-Cell Co-Stimulator Ligand (ICOSLG) (AA 23-149) antibodyICOSLG 适用: 人 IHC, ELISA, FACS, IF 宿主: 小鼠 Monoclonal ICOSL-3111 unconjugated
anti-Inducible T-Cell Co-Stimulator Ligand (ICOSLG) (AA 19-256) antibodyICOSLG 适用: 人 ELISA, FACS 宿主: 小鼠 Monoclonal 1G6E1 unconjugated
anti-Inducible T-Cell Co-Stimulator Ligand (ICOSLG) (AA 58-249) antibodyICOSLG 适用: 小鼠 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
anti-Inducible T-Cell Co-Stimulator Ligand (ICOSLG) (AA 23-149) antibodyICOSLG 适用: 人 IHC, ELISA 宿主: 小鼠 Monoclonal ICOSL-3260 unconjugated
anti-Inducible T-Cell Co-Stimulator Ligand (ICOSLG) (AA 197-246) antibodyICOSLG 适用: 人 WB, IHC, IHC (p) 宿主: 兔 Polyclonal unconjugated
anti-Inducible T-Cell Co-Stimulator Ligand (ICOSLG) (AA 19-256) antibodyICOSLG 适用: 人 WB, IHC 宿主: 兔 Polyclonal unconjugated
anti-Inducible T-Cell Co-Stimulator Ligand (ICOSLG) (AA 19-120) antibodyICOSLG 适用: 人, 小鼠 WB, ELISA, FACS 宿主: 兔 Polyclonal unconjugated
anti-Inducible T-Cell Co-Stimulator Ligand (ICOSLG) antibodyICOSLG 适用: 小鼠 FACS, BR 宿主: 兔 Chimeric HK5-3 unconjugated Recombinant Antibody
anti-Inducible T-Cell Co-Stimulator Ligand (ICOSLG) (AA 20-302) antibodyICOSLG 适用: 人 WB, ELISA 宿主: 小鼠 Monoclonal 1E2 unconjugated
-
-
应用备注
- Optimal dilution of the ICOSLG antibody should be determined by the researcher.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol, 0.4-0.5 mg/mL BSA
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- -20 °C
-
储存方法
- Store the ICOSLG antibody at -20oC.
-
-
- ICOSLG (Inducible T-Cell Co-Stimulator Ligand (ICOSLG))
-
别名
- ICOSLG
-
背景
-
ICOSLG antibody / CD275 detects inducible T-cell co-stimulator ligand, a member of the B7 family of immune regulatory proteins. ICOSLG interacts with its receptor, ICOS, which is expressed on activated T cells. This interaction delivers essential costimulatory signals that regulate T-cell activation, proliferation, differentiation, and cytokine production. The ICOS-ICOSLG pathway is especially critical for the development and function of follicular helper T cells, which support germinal center reactions and promote high-affinity antibody responses.
Research using ICOSLG antibody / CD275 has revealed its central role in adaptive immunity. Antigen-presenting cells such as dendritic cells, B cells, and macrophages express ICOSLG, providing the signals needed for robust T-cell dependent immune responses. Engagement of ICOS by ICOSLG promotes B-cell class switching, enhances antibody secretion, and ensures the generation of long-lived plasma cells and memory B cells. These functions make ICOSLG indispensable for establishing effective humoral immunity.
Dysregulation of ICOSLG expression or signaling is linked to immune-related diseases. Overactivation of the ICOS-ICOSLG axis can drive autoimmunity by supporting excessive T-cell responses and autoantibody production. Conversely, mutations or deficiencies impair T-cell function and result in immunodeficiency syndromes marked by recurrent infections and poor antibody responses. Genetic studies have associated ICOSLG polymorphisms with systemic lupus erythematosus, type 1 diabetes, and inflammatory bowel disease, highlighting its importance in immune tolerance and regulation.
In transplantation, ICOSLG contributes to graft rejection by enhancing alloreactive T-cell activity. Targeting this pathway has been explored as a strategy to prolong graft survival and reduce immune-mediated damage. Conversely, therapeutic stimulation of the ICOS-ICOSLG axis has potential in vaccine design, where stronger antibody responses are desired.
Oncology research has shown that ICOSLG expression within the tumor microenvironment can significantly affect anti-tumor immunity. In some cases, ICOSLG enhances T-cell activity against cancer cells, while in others it may contribute to immune evasion depending on the balance of regulatory and effector T-cell populations. Therapies modulating the ICOS-ICOSLG pathway are being investigated as potential adjuncts to checkpoint blockade and other immunotherapies, making it a promising focus for translational research.
Antibodies against ICOSLG are validated for flow cytometry, western blot, and immunohistochemistry. These reagents allow researchers to measure expression levels across immune subsets, evaluate tissue localization, and monitor functional changes in experimental models. By enabling precise detection of ICOSLG, they support studies into immune regulation, autoimmunity, cancer, and transplant biology.
NSJ Bioreagents supplies this ICOSLG antibody / CD275 for research in immunology, oncology, and translational medicine. -
UniProt
- O75144
-
途径
- Production of Molecular Mediator of Immune Response, Activated T Cell Proliferation
抗原
-
